臨床眼科76巻3号

2022年03月発行

特集 第75回日本臨床眼科学会講演集［1］ 特別講演

加齢黄斑変性の治療：より良いQuality of Lifeを目指して

著者： 大路正人¹

所属機関： ¹滋賀医科大学眼科学講座

ページ範囲：P.271 - P.282

　加齢黄斑変性（AMD）は失明原因として重要な疾患の1つであり，社会の高齢化に伴って今後も増加が予測されている。AMDの診断および治療は，過去20年程度の間に飛躍的に進歩したが，いまだ十分に満足できるものではない。患者の求めるものは，良好な視力と少ない負担を含めたトータルとしての良好なQuality of Life（QOL）である。AMD患者におけるQOLを向上させるためになされてきた研究のなかで，治療法に関するこれまでの歩みと現状について，自験例を中心に呈示する。

参考文献

1）Morizane Y, Morimoto N, Fujiwara A et al：Incidence and causes of visual impairment in Japan：the first nation-wide complete enumeration survey of newly certified visually impaired individuals. Jpn J Ophthalmol 63：26-33, 2019

2）World Health Organization 2019：World report on vision. 2019

3）Yasuda M, Kiyohara Y, Hata Y et al：Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology 116：2135-2140, 2009

4）Kawasaki R, Wang JJ, Ji GJ et al：Prevalence and risk factors for age-related macular degeneration in an adult Japanese population：the Funagata study. Ophthalmology 115：1376-1381, 2008

5）Sawada T, Yasukawa T, Imaizumi H et al：Ten-year changes in visual acuity at baseline and at 2 years after treatment in a Japanese population with age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 259：1191-1198, 2021（http://creativecommons.org/licenses/by/4.0/）

6）髙橋寛二・石橋達朗・小椋祐一郎・他：加齢黄斑変性の分類と診断基準．日眼会誌112：1076-1084，2008

7）Sho K, Takahashi K, Yamada H et al：Polypoidal choroidal vasculopathy：incidence, demographic features, and clinical characteristics. Arch Ophthalmol 121：1392-1396, 2003

8）Maruko I, Iida T, Saito M et al：Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144：15-22, 2007

9）Mori K, Horie-Inoue K, Gehlbach PL et al：Phenotype and genotype characteristics of age-related macular degeneration in a Japanese population. Ophthalmology 117：928-938, 2010

10）Coscas G, Yamashiro K, Coscas F et al：Comparison of exudative age-related macular degeneration subtypes in Japanese and French patients：multicenter diagnosis with multimodal imaging. Am J Ophthalmol 158：309-318, 2014

11）Macular Photocoagulation Study Group：Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 100：912-918, 1982

12）Friberg TR, Pandya A, Nazari K：Transpupillary thermotherapy（TTT）for age-related macular degeneration. Semin Ophthalmol 16：70-80, 2001

13）Merrill PT, LoRusso FJ, Lomeo MD et al：Surgical removal of subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology 106：782-789, 1999

14）Machemer R, Steinhorst UH：Retinal separation, retinotomy, and macular relocation：Ⅱ A surgical approach for age-related macular degeneration? Graefes Arch Clin Exp Ophthalmol 231：635-641, 1993

15）Cekic O, Ohji M, Hayashi A et al：Foveal translocation surgery in age-related macular degeneration. Lancet 354：340, 1999

16）Ohji M, Fujikado T, Kusaka S et al：Comparison of three techniques of foveal translocation in patients with subfoveal choroidal neovascularization resulting from age-related macular degeneration. Am J Ophthalmol 132：888-896, 2001

17）Treatment of age-related macular degeneration with photodynamic therapy（TAP）Study Group：Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin：one-year results of 2 randomized clinical trials-TAP report. Arch Ophthalmol 117：1329-1345, 1999

18）Japanese age-related macular degeneration trial（JAT）Study Group：Japanese age-related macular degeneration trial：1-year results of photodynamic therapy with verteporfin in Japanese patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 136：1049-1061, 2003

19）Brown DM, Kaiser PK, Michels M et al：Ranivizumab versus verteporfin for neovascular age-related macular degeneration. New Engl J Med 355：1432-1444, 2006

20）The Runners-up. Science 314：1850-1855, 2006

21）Niwa Y, Kakinoki M, Sawada T et al：Ranibuzumab and Aflibercept：Intraocular pharmacokinetics and their effects on aqueous VEGF level in vitrectomized and non-vitrectomized macaque eyes. Invest Ophthalmol Vis Sci 56：6501-6505, 2015

22）Wang X, Sawada T, Kakinoki M et al：Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol 252：1033-1039, 2014

23）Sawada T, Wang X, Sawada O et al：Aqueous vascular endothelial growth factor and aflibercept concentrations after bimonthly intravitreal injections of aflibercept for age-related macular degeneration. Clin Exp Ophthalmol 46：46-53, 2018

24）Wang X, Sawada T, Sawada O et al：Serum and plasma vascular endothelial growth factor concentrations before and after intravitreal injection of aflibercept or ranibizumab for age-related macular degeneration. Am J Ophthalmol 158：738-744, 2014

25）Ichiyama Y, Sawada T, Sawada O et al：The correlation between aqueous vascular endothelial growth factor level and clinical activity in neovascular age-related macular degeneration. Retina 41：111-117, 2021

26）Ohji M, Takahashi K, Okada AA et al：Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration：52- and 96-week findings from ALTAIR：A randomized controlled trial. Adv Ther 37：1173-1187, 2020（http://creativecommons.org/licenses/by/4.0/）

27）Ohji M, Okada AA, Sasaki K et al：Relationship between retinal fluid and functional outcomes in patients with exudative age-related macular degeneration treated with intravitreal aflibercept using a treat-and-extend regimen：subgroup and post hoc analyses from the ALTAIR study Graefes Arch Clin Exp Ophthalmol 259：3637-3647, 2021（http://creativecommons.org/licenses/by/4.0/）

28）Eylea Summary of product characteristics EMA（https://www.ema.europa.eu/en/documents/product-information/eylea-epar-product-information_en.pdf）（閲覧日：2022年1月7日）

29）Bennett SR, Folk JC, Blodi CF et al：Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 109：33-37, 1990

30）Avery RL, Fekrat S, Hawkins BS et al：Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 16：183-189, 1996

31）de Juan E Jr, Machemer R：Vitreous surgery for hemorrhagic and fibrous complications of age-related macular degeneration. Am J Ophthalmol 105：25-29, 1988

32）Peyman GA, Nelson NC Jr, Alturki W et al：Tissue plasminogen activating factors assisted removal of subretinal hemorrhage. Ophthalmic Surg 22：575-582, 1991

33）Kamei M, Tano Y, Maeno T et al：Surgical removal of submacular hemorrhage using tissue plasminogen activator and perfluorocarbon liquid. Am J Ophthalmol 121：267-275, 1996

34）Heriot WJ：Further experience in management of submacular hemorrhage with intravitreal TPA. In：Program and abstracts of Vitreoretinal Update 1997；October 24-25, 1997；San Francisco, Calif. Pages 82-84

35）Ohji M, Saito Y, Hayashi A et al：Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 116：1326-1332, 1998

36）Fujikawa M, Sawada O, Miyake T et al：Comparison of pneumatic displacement for submacular hemorrhages with gas alone and gas plus tissue plasminogen activator. Retina. 33：1908-1914, 2013

37）PAT-J Survey 2018日本網膜硝子体学会　会員専用サイト（http://secure2.jtbcom.co.jp/jrvs/）（閲覧日：2022年1月21日）

38）大路正人・本倉雅信・斉藤喜博・他：網膜下出血に対する硝子体手術—周辺部網膜からの排出．眼臨医報90：1101，1996

39）Oshima Y, Ohji M, Tano Y：Pars plana vitrectomy with peripheral retinotomy after injection of preoperative intravitreal tissue plasminogen activator：a modified procedure to drain massive subretinal hemorrhage. Br J Ophthalmol 91：193-198, 2007

40）Liu H, Zhang LY, Li XX et al：23-gauge vitrectomy with external drainage therapy as a novel procedure to displace massive submacular hemorrhage secondary to polypoidal choroidal vasculopathy. Medicine（Baltimore）95：e4192, 2016